These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32495012)

  • 1. Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease.
    Rapista N; Sarkar S; Chaudhary R
    J Thromb Thrombolysis; 2020 Nov; 50(4):982-983. PubMed ID: 32495012
    [No Abstract]   [Full Text] [Related]  

  • 2. Spontaneous, Life-Threatening Hemorrhagic Cardiac Tamponade Secondary to Rivaroxaban.
    Kham NM; Song M
    Am J Ther; 2016; 23(4):e1128-31. PubMed ID: 26035030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis.
    Ito H
    Eur J Intern Med; 2024 Jun; 124():154-155. PubMed ID: 38342714
    [No Abstract]   [Full Text] [Related]  

  • 4. [Good efficacy and safety profile in clinical practice].
    MMW Fortschr Med; 2015 Nov; 157(20):66-7. PubMed ID: 26977521
    [No Abstract]   [Full Text] [Related]  

  • 5. [Acute tubulo-interstitial nephritis due to RIVAROXABAN (XARELTO)].
    Dantec A; Virot JS; Filancia A; Angonin R; Nefti H
    Presse Med; 2017 May; 46(5):541-542. PubMed ID: 28483286
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
    Lindner SM; Fordyce CB; Hellkamp AS; Lokhnygina Y; Piccini JP; Breithardt G; Mahaffey KW; Singer DE; Hacke W; Halperin JL; Hankey GJ; Berkowitz SD; Nessel CC; Becker RC; Fox KA; Patel MR;
    Circulation; 2017 Mar; 135(10):1001-1003. PubMed ID: 28264892
    [No Abstract]   [Full Text] [Related]  

  • 7. Rivaroxaban-associated intracranial hemorrhage in Saudi atrial fibrillation patients.
    Alkhotani A; Alrishi N; Alharthi M; Alzahrani W
    Medicine (Baltimore); 2020 Nov; 99(48):e23316. PubMed ID: 33235091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation.
    Tamayo SG; Simeone JC; Nordstrom BL; Patel MR; Yuan Z; Sicignano NM; Peacock WF
    J Am Coll Cardiol; 2016 Sep; 68(10):1144-6. PubMed ID: 27585515
    [No Abstract]   [Full Text] [Related]  

  • 9. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
    Colonna P; Ammirati F;
    G Ital Cardiol (Rome); 2016 Nov; 17(11):932-939. PubMed ID: 27996999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
    Fordyce CB; Hellkamp AS; Lokhnygina Y; Lindner SM; Piccini JP; Becker RC; Berkowitz SD; Breithardt G; Fox KA; Mahaffey KW; Nessel CC; Singer DE; Patel MR;
    Circulation; 2016 Jul; 134(1):37-47. PubMed ID: 27358435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rivaroxaban in high-risk patients].
    Špinar J; Špinarová L
    Vnitr Lek; 2017; 63(6):424-430. PubMed ID: 28840739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy.
    Sholzberg M; Xu Y
    JAMA; 2018 Oct; 320(14):1485-1486. PubMed ID: 30242329
    [No Abstract]   [Full Text] [Related]  

  • 16. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
    Karthikeyan G; Connolly SJ; Ntsekhe M; Benz A; Rangarajan S; Lewis G; Yun Y; Sharma SK; Maklady F; Elghamrawy AE; Kazmi K; Cabral TTJ; Dayi H; Changsheng M; Gitura BM; Avezum A; Zuhlke L; Lwabi P; Haileamlak A; Ogah O; Chillo P; Paniagua M; ElSayed A; Dans A; Gondwe-Chunda L; Molefe-Baikai OJ; Gonzalez-Hermosillo JA; Hakim J; Damasceno A; Kamanzi ER; Musuku J; Davletov K; Connolly K; Mayosi BM; Yusuf S;
    Am Heart J; 2020 Jul; 225():69-77. PubMed ID: 32474206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network Meta-Analysis Comparing Apixaban Versus Rivaroxaban in Morbidly Obese Patients With Atrial Fibrillation.
    Kido K; Shimizu M; Shiga T; Hashiguchi M
    Am J Cardiol; 2020 Nov; 134():160-161. PubMed ID: 32916147
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation.
    Aronow WS; Shamliyan TA
    Am J Ther; 2019; 26(6):e679-e703. PubMed ID: 30461433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pruritus and rivaroxaban].
    Aguilar-Shea AL; Gallardo-Mayo C
    Semergen; 2018; 44(4):e96-e97. PubMed ID: 29439912
    [No Abstract]   [Full Text] [Related]  

  • 20. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.